Synopsis:
Unifi Capital acquired 72.4 lakh Marksans Pharma shares (1.6 percent stake) via BSE for nearly Rs. 167.6 crore, at an average price of Rs. 231.5 per share.
During Tuesday’s trading session, shares of a company engaged in the research, manufacturing & marketing of generic pharmaceutical formulations are in focus on the stock exchanges, after an asset management company bought stake in the company worth more than Rs. 167 crores.
At 11:05 a.m., the shares of Marksans Pharma Limited were trading in the red at Rs. 225.4 on BSE, down by around 0.5 percent, as against its previous closing price of Rs. 226.45, with a market cap of Rs. 10,214.3 crores. The stock has delivered positive returns of more than 11 percent in the last one year, but has fallen by nearly 14 percent in the last one month.
What’s the News
According to the latest bulk deal data, an asset management company (AMC), Unifi Capital Private Limited, bought around 72.4 lakh equity shares of Marksans Pharma Limited, representing a 1.6 percent stake via BSE. The transaction was valued at around Rs. 167.6 crores, with the shares bought at an average price of Rs. 231.5 per share.
Financials & more
Marksans Pharma reported a significant growth in its revenue from operations, showing a year-on-year increase of around 26 percent from Rs. 560 crores in Q4 FY24 to Rs. 708 crores in Q4 FY25.
Similarly, its net profit increased during the same period from Rs. 78 crores to Rs. 91 crores, representing a rise of about 17 percent YoY. The company’s financial results for Q1 FY26 will be announced on 12th August 2025.
Marksans Pharma Limited is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. It operates two manufacturing facilities in Goa and maintains two R&D centres, one located in Goa and the other in Navi Mumbai.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Pharma stock in focus after asset management company bought stake worth ₹167 via bulk deal appeared first on Trade Brains.